AstraZeneca beats expectations and raises guidance despite China troubles

El epidemiólogo e infectólogo, Carlos Álvarez, explicó en qué consisten los extremadamente raros eventos adversos de la vacuna 

AstraZeneca will set up a R&D centre and an AI innovation centre in Shanghai, as well as create a $1bn fund that would invest in healthcare start-ups.

London-Based drug firm, AstraZeneca has entered into a new field of developing drugs using proteins secreted by the cells called as "Secretome". It has

Zurampic (lesinurad), a drug to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, has been approved by the US Food and

The WHO has recognised TTS as a rare but serious adverse event linked to specific Covid-19 vaccines.

AstraZeneca will set up a R&D centre and an AI innovation centre in Shanghai, as well as create a $1bn fund that would invest in healthcare start-ups.

VAT treatment of vouchers provided to employees under salary sacrifice You will no doubt have been made aware of the recent CJEU (formerly European Court of Justice) ruling in AstraZeneca. The case involved AstraZeneca and the retail vouchers that ...

M&A in the pharma sector marches on unabated - AstraZeneca buying a 55 percent stake in biotech Acerta Pharma for $4.0 billion to give it new cancer drugs. Hayley Platt reports.

An AstraZeneca diabetes drug that brought in more than $1.5 billion in sales last year has won an FDA nod expanding its use to adults with systolic heart failure, a condition in which the heart struggles to pump with enough force to push enough blood into circulation. The drug, the once-daily pill dapagliflozin (Farxiga), was […]

Firm’s recent success could have been very different had it been bought out by Pfizer in 2014

It’s perhaps not surprising that the worth of healthcare companies should emerge during a global pandemic, but we should offer thanks for the UK’s big pharma twins – AstraZeneca and GlaxoSmithKline.

The former, with its share price at all-time high, is now jostling with Shell and Unilever for the title of biggest company in the FTSE 100 index. Successful research bets, especially on cancer drugs, have transformed Astra.

Drugmaker will manufacture and distribute vaccine if human trials are successful

• Coronavirus – latest updates
• See all our coronavirus coverage

AstraZeneca, the Cambridge-based pharmaceutical group, is teaming up with Oxford University to manufacture and distribute a coronavirus vaccine if clinical trials currently under way show it is effective.

News of the partnership boosted AstraZeneca’s share price, helping it to become Britain’s most valuable company by market capitalisation.

Related: The hunt for a coronavirus vaccine – a perilous and uncertain path

A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with the former agreeing to aid in the development and large-scale manufacture of the latter’s potential recombinant adenovirus vaccine for the prevention of novel coronavirus infection.

AZ has pledged to make the vaccine at cost for the duration of the pandemic

AstraZeneca has watched superstar SGLT2 diabetes med Farxiga nail trial after trial in highly coveted kidney and heart failure indications, with the FDA expediting reviews to back them up. The one thing AstraZeneca was missing? The agency taking Farxiga across the finish line. 

AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration.

This Administration is committed to recovering taxpayer money lost to health care fraud, whether it’s by bringing cases against common criminals operating out of vacant storefronts or executives at some of the nation’s biggest companies.

Partnership that would prioritise UK could produce 100m doses by year-end if treatment is effective

Companies analysis from our sister publication